Kecerdasan buatan
Protokol Darurat Usang Siap Dimodernisasi oleh Pembelajaran Mesin
New data from Osaka University has shown that machine learning’s rapidly increasing capabilities may now extend to emergency situations. Tim peneliti telah menunjukkan that the technology can now effectively assist in determining appropriate candidates for Tranexamic Acid, reducing mortality rates among trauma patients.
Apa Itu Tranexamic Acid (TXA)?
Most medications are simply treatments for some sort of condition. A few, however, can be truly lifesaving. One of these is Tranexamic Acid, or ‘TXA’. On its simplest level, TXA is given to patients to stop extensive bleeding, typically stemming from some sort of trauma.
Jika ditelusuri lebih dalam, TXA bekerja dengan mengurangi dan mencegah perdarahan berkelanjutan dengan mempromosikan pembentukan bekuan dalam tubuh. Ia melakukannya dengan mencegah pembentukan enzim yang dikenal sebagai plasmin yang berfungsi memecah protein penting untuk pembekuan – fibrin.
Normally, the presence of plasmin is a good thing, as it prevents excessive clotting and a litany of ailments (e.g., strokes, pulmonary embolism, deep vein thrombosis, myocardial infarction, etc,.) that may result. However, in an emergency situation where bleeding needs to be controlled, TXA’s ability to prevent its formation is crucial.
Menyelamatkan Nyawa dalam Situasi Darurat dengan Pembelajaran Mesin
Whether it is a frontline Paramedic working to stabilize a patient in the back of a moving ambulance, or a Nurse working alongside a team of healthcare professionals in an emergency room, TXA remains an important tool for managing unchecked bleeding resulting from trauma. It is important to recognize, though, that TXA is not appropriate for every patient, as it is often accompanied by serious side-effects, making the determination for delivery a difficult one.
Menyadari bahwa TXA tidak bermanfaat secara universal karena potensi efek samping, studi yang disebutkan di atas berfokus pada mengidentifikasi subkelompok pasien trauma tertentu yang paling mungkin mendapat manfaat dari pengobatan TXA. Di masa depan, kemampuan untuk mengidentifikasi kandidat ini dapat memainkan peran penting dalam memodernisasi protokol yang ada untuk menentukan kelayakan pemberian.
Dengan menggunakan teknik pembelajaran mesin, para peneliti menganalisis data dari lebih dari 50.000 pasien dalam Japan Trauma Data Bank untuk mengidentifikasi delapan fenotipe trauma yang berbeda (kelompok berdasarkan sifat yang dapat diamati). Mereka kemudian meneliti dampak TXA pada fenotipe tersebut terkait mortalitas di rumah sakit. Temuan menunjukkan bahwa subkelompok tertentu mengalami penurunan mortalitas yang signifikan ketika diobati dengan TXA, sementara yang lain tidak mendapatkan manfaat.
The study underscores the diverse presentations of trauma patients, whose injuries vary widely in type and severity, making it challenging to predict treatment effectiveness on an individual basis. The goal of this research is to enhance personalized care for trauma patients, thereby improving the overall quality of care and survival rates in this high-risk population. This approach to patient-specific treatment could lead to more effective use of TXA in trauma care, reducing unnecessary side effects and optimizing outcomes – all thanks to machine learning.
Machine Learning: A Central Catalyst Across Disruptive Technologies
This study is the latest in a growing crop of examples highlighting how subsets of artificial intelligence, like machine learning, can excel as a central catalyst or ‘core technology’ across nearly any sector – sebuah realisasi yang ditekankan dalam ‘Big Ideas 2024’ milik Ark Invest.
Much of this is attributed to AI’s ability to process and recognize patterns within vast amounts of data. It can do so more efficiently than any human and is advancing itself quicker and quicker.
Spesialis Pembelajaran Mesin
While it may be some time before machine learning is used to determine whether a patient should be given TXA is put into practice, there are multiple companies already working to develop the technology further. In fact, some have already begun to incorporate it into other facets of healthcare that are just as important.
*Angka yang disediakan di bawah ini akurat pada saat penulisan dan dapat berubah. Setiap investor potensial harus memverifikasi metrik*
1. NVIDIA
(NVDA
)
(NVDA )
| Kapitalisasi Pasar | Forward P/E 1 Thn. | Pendapatan per Saham (EPS) |
| 2,179,359,750,000 | 38.31 | $11.94 |
NVIDIA has been at the forefront of AI development, leveraging its powerful GPU technology to advance various sectors, including healthcare. In healthcare, NVIDIA’s AI platforms are used to accelerate drug discovery, medical imaging, and genetic analysis. For instance, their GPUs enable faster processing of large datasets for tasks like imaging diagnostics, helping to identify diseases from X-rays and MRIs with greater accuracy and speed.
NVIDIA collaborates with research institutions and healthcare organizations to develop AI tools that predict diseases, improve patient outcomes, and reduce healthcare costs. Through these initiatives, NVIDIA enhances existing healthcare applications and pioneers new ways to diagnose and treat diseases using the power of AI.
At the time of writing, NVDA was listed by the majority of analysts as a ‘Beli Kuat’
2. Powerful Medical
The flagship product/service of Powerful Medical is known as PMCardio. This is a platform designed to assist healthcare professionals in analyzing, interpreting, diagnosing, and treating cardiac events.
It uses machine learning to analyze ECGs and compare them against a vast database of patient records. This allows PMcardio to detect myocardial infarctions, aka ‘heart attacks’, and other abnormalities accurately and quickly.
The platform stands out for its ability to provide precise diagnoses at the initial point of contact, which is crucial for timely intervention in cardiovascular emergencies. PMcardio’s technology is particularly significant because it helps to address the critical gap in detecting heart conditions that may not be apparent through traditional diagnostic methods.
By integrating AI into its operations, PMcardio offers healthcare professionals a powerful tool that improves care coordination, streamlines the triage process, and ensures early and accurate detection of potentially life-threatening cardiac events. This advancement in medical technology highlights the potential of AI to revolutionize the field of cardiovascular diagnostics by enhancing the capability to predict and treat heart diseases effectively.
Baru-baru ini pada 1 Maret 2024, PMCardio berhasil mengamankan pendanaan €7,5 juta dari European Innovation Council untuk melanjutkan pengembangan alat diagnostik berbasis AI-nya, menunjukkan potensinya dalam mengurangi salah satu penyebab kematian utama di dunia.
